Difelikefalin in Chinese patients with chronic kidney disease-associated pruritus
Clinical Kidney Journal · 01.04.2026 · 19 (4)
DOI: 10.1093/ckj/sfag031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 06.02.2026. Verfasst von Li Zuo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Peking University People's Hospital, Beijing, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dashiell Mycroft, Vifor Fresenius Medical Care Renal Pharma.
Abstract (Originalsprache)
Background
Chronic kidney disease-associated pruritus (CKD-aP) is a common and debilitating condition in patients receiving in-centre haemodialysis. This study evaluated the efficacy and safety of difelikefalin (a new, intravenous treatment for moderate-to-severe CKD-aP approved in >40 countries) in a Chinese population receiving haemodialysis.
Methods
This Phase 3, multicentre, randomized placebo-controlled study included a 12-week double-blind treatment period, during which patients received either difelikefalin or placebo, followed by an optional 14-week open-label extension, in which all patients received difelikefalin. Endpoints included change from baseline in the Worst Itching Intensity Numerical Rating Scale (WI-NRS) at Week 4 (primary endpoint), the percentage of patients achieving a clinically relevant ≥3-point change in WI-NRS, patient-reported health-related quality-of-life measures, and incidence of adverse events.
Results
Difelikefalin-treated patients showed significantly greater improvements in least squares mean change from baseline in WI-NRS at Week 4 of the double-blind period compared with placebo [difelikefalin minus placebo: −0.81 (95% confidence interval: −1.25, −0.37); P = .0003], and patients with ≥3-point improvement in WI-NRS at Week 12 (48.7% versus 33.8%, nominal P = .0235). Difelikefalin also improved health-related quality of life, with clinically relevant changes observed in 5-D itch and Skindex-10 in most patients at Week 4 of the open-label extension (estimated ≥62% and ≥56%, respectively). Adverse events were mostly mild or moderate in severity and generally consistent with the known safety profile of difelikefalin.
Conclusion
Difelikefalin effectively reduced pruritus intensity and improved quality of life in Chinese patients with CKD-aP receiving haemodialysis, supporting its use in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Peking University People's Hospital, Beijing, China.
- Department of Nephrology, Zhongshan Hospital Xiamen University, Xiamen, China.
- Department of Nephrology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
- Department of Nephrology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Nephrology, Zhuzhou Central Hospital, Zhuzhou, China.
- Department of Nephrology, Wuxi People's Hospital, Wuxi, China.
ORCID-Profile: Liangying Gan
Förderung
- Dashiell Mycroft
- Vifor Fresenius Medical Care Renal Pharma
Zitieren
APA
Zuo, L., Gan, L., Guan, T., He, W., Ye, H., Peng, Q., Liu, B., Dai, H., Ba, Y., Xue, L., Lowe, M., & Enoiu, M. (2026). Difelikefalin in Chinese patients with chronic kidney disease-associated pruritus. Clinical Kidney Journal, 19(4). https://doi.org/10.1093/ckj/sfag031
Vancouver
Zuo L, Gan L, Guan T, He W, Ye H, Peng Q, et al. Difelikefalin in Chinese patients with chronic kidney disease-associated pruritus. Clinical Kidney Journal. 2026;19(4). doi:10.1093/ckj/sfag031
BibTeX
@article{Zuo2026,
author = {Zuo, Li and Gan, Liangying and Guan, Tianjun and He, Weiming and Ye, Hong and Peng, Qingfeng and Liu, Bin and Dai, Houyong and Ba, Yinggui and Xue, Lanfen and Lowe, Murray and Enoiu, Milica},
title = {Difelikefalin in Chinese patients with chronic kidney disease-associated pruritus},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {4},
doi = {10.1093/ckj/sfag031}
}
EUVIMED